Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 2

被引:0
|
作者
Ton, Minh That [1 ]
Ho, Tri Huynh Quang [2 ]
Nguyen, Viet Lan [3 ]
Pham, Hung Manh [3 ,4 ]
Van Hoang, Sy [3 ,4 ]
Vo, Nhan Thanh [5 ,6 ]
Nguyen, Thai Quoc [3 ]
Pham, Linh Tran [3 ]
Mai, Ton Duy [4 ,7 ,8 ]
Nguyen, Thang Huy [9 ,10 ]
机构
[1] Tam Duc Heart Hosp, Ho Chi Minh City, Vietnam
[2] Heart Inst, Surg Intens Care Unit, Ho Chi Minh City, Vietnam
[3] Bach Mai Hosp, Vietnam Heart Inst, Hanoi, Vietnam
[4] Hanoi Med Univ, Hanoi, Vietnam
[5] Cho Ray Hosp, Cardiovasc Dept, Ho Chi Minh City, Vietnam
[6] Vinmec Hosp, Cardiovasc Ctr, Ho Chi Minh City, Vietnam
[7] Bach Mai Hosp, Stroke Ctr, Hanoi, Vietnam
[8] VNU Univ Med & Pharm, Hanoi, Vietnam
[9] Peoples 115 Hosp, Cerebro Vasc Dis Dept, 527 Hanh St,Dist 10,Ward 12, Ho Chi Minh City 700000, Vietnam
[10] Pham Ngoc Thach Univ Med, Ho Chi Minh City, Vietnam
关键词
Atrial fibrillation; renal impairment; diabetes; coronary artery disease; elderly; bioprosthetic valve; DIABETES-MELLITUS; ELDERLY-PATIENTS; EMBOLISM TRIAL; RENAL-FUNCTION; ANTITHROMBOTIC THERAPY; RISK STRATIFICATION; WARFARIN; OUTCOMES; RIVAROXABAN; DABIGATRAN;
D O I
10.15420/ecr.2023.25
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Part 1 of this review provided an overview of AF in Vietnam, with a particular focus on primary and secondary stroke prevention. Part 2 explores the management of AF in special, high-risk and clinically common patient populations, including those with renal impairment, diabetes, the elderly, and those with coronary artery disease. Furthermore, Part 2 addresses the challenges posed by patients with AF who have a bioprosthetic valve, a group situated in a grey area of consideration. Managing AF in these patient groups presents unique clinical challenges that require careful consideration. Physicians are tasked with addressing specific clinical questions to identify the optimal anticoagulation strategy for each individual. To inform these decisions, subgroup analyses from pivotal studies are presented alongside real-world data derived from clinical practice. By synthesising available information and considering the nuanced clinical context, the aim is to provide informed perspectives that align with current medical knowledge and contribute to the enhancement of patient care in these challenging scenarios.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies
    Liu, Xin
    Xu, Zi-Xuan
    Yu, Peng
    Yuan, Ping
    Zhu, Wen-Gen
    CARDIOVASCULAR DRUGS AND THERAPY, 2020, 34 (04) : 569 - 578
  • [32] Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation
    Walid Saliba
    American Journal of Cardiovascular Drugs, 2015, 15 : 323 - 335
  • [33] Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention
    Gorczyca, Iwona
    Michalska, Anna
    Chrapek, Magdalena
    Jelonek, Olga
    Walek, Pawel
    Wozakowska-Kaplon, Beata
    CARDIOLOGY JOURNAL, 2021, 28 (06) : 896 - 904
  • [34] Clinical Significance of Non-Vitamin K Antagonist Oral Anticoagulants in the Management of Atrial Fibrillation
    Santarpia, Giuseppe
    Curcio, Antonio
    Sibilio, Gerolamo
    Indolfi, Ciro
    CIRCULATION JOURNAL, 2015, 79 (05) : 914 - 923
  • [35] Outcomes of non-vitamin K oral anticoagulants for secondary prevention in ischemic stroke with atrial fibrillation
    Nam, Ki-Woong
    Kwon, Hyung-Min
    Lee, Yong-Seok
    Won, Sung-Ho
    Moon, Hye-Sung
    Park, Jong-Ho
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [36] How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?
    De Caterina, Raffaele
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2016, 18 (0I) : 1 - 6
  • [37] Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia
    Janion-Sadowska, Agnieszka
    Papuga-Szela, Elbieta
    Lukaszuk, Robert
    Chrapek, Magdalena
    Undas, Anetta
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2018, 72 (03) : 153 - 160
  • [38] The Role of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) in Atrial Fibrillation: Treatment Management Based on Patient and Drug Characteristics
    Ergene, Oktay
    Aras, Dursun
    Kaymaz, Cihangir
    Arsava, Ethem Murat
    Gonen, Can
    Gurkas, Erdem
    Arslan, Ugur
    Cagirici, Goksel
    Cay, Serkan
    Kilickap, Mustafa
    Kanat, Selcuk
    Ozpelit, Ebru
    Vatansever, Fahriye
    Kilickesmez, Kadriye
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2022, 50 (05): : 356 - 370
  • [39] Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation
    Sanmartin-Fernandez, Marcelo
    Marzal-Martin, Domingo
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2017, 23 (07) : 711 - 724
  • [40] Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin
    Huang, Huei-Kai
    Liu, Peter Pin-Sung
    Hsu, Jin-Yi
    Lin, Shu-Man
    Peng, Carol Chiung-Hui
    Wang, Jen-Hung
    Yeh, Jih-, I
    Loh, Ching-Hui
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (02):